Tirzepatide is a dual GIP/GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management
Each patient is matched with a licensed provider for initial evaluation and ongoing dosage management, and the platform emphasizes high ongoing support including regular provider check-ins throughout treatment
Avoid sites that skip evaluations, promise guaranteed approval, or advertise suspiciously low prices
These SCFAs play a crucial role in anti-inflammatory pathways and signaling across various organs, contributing to overall host health (Markowiak-Kope and liewska, 2020)
How is this different from just going to a med spa
Transparency and safety are our highest priorities, and we encourage every Canadian to consult with a family doctor, pharmacist, or nurse practitioner before starting a new regimen